Catalio Capital Management »

Definium Therape shares owned by Catalio Capital Management

Quarter-by-quarter ownership of Definium Therape (DFTX) shares owned by Catalio Capital Management from 13F filings

Historical chart of Catalio Capital Management investment in Definium Therape

Tip: Access up to 7 years of quarterly data

All positions including Definium Therape held by Catalio Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Definium Therape by Catalio Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $20M 1.0M 18.90

More positions owned by Catalio Capital Management

Dianthus Therapeutics (DNTH)
Bridgebio Pharma (BBIO)
Ascendis Pharma A/s Sponsored Adr (ASND)
Bristol Myers Squibb (BMY)
Syndax Pharmaceuticals (SNDX)
Gilead Sciences (GILD)
Terns Pharmaceuticals (TERN)
Definium Therapeutics Com Shs (DFTX)
Soleno Therapeutics (SLNO)
Boston Scientific Corporation (BSX)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation (INCY)
Cytokinetics Com New (CYTK)
Natera (NTRA)
Corvus Pharmaceuticals (CRVS)

View all positions for Catalio Capital Management

Top funds holding Definium Therape

BlackRock
Driehaus Capital Management
Henderson Group
Deep Track Capital
Marshall Wace
Geode Capital Management
Octagon Capital Advisors
Commodore Capital
Trails Edge Capital Partners
Goldman Sachs Group
Arrowpoint Asset Management
Citadel Advisors
Candriam Luxembourg S.C.A.
Balyasny Asset Management
Two Sigma Investments

View all funds holding Definium Therape